Profos and bioMérieux sign agreement
BioMérieux develops, produces and markets diagnostic products (apparatus, reagents and software) for the identification and demonstration of bacteria, cardiovascular disease, carcinomas, contamination in the foodstuff and pharmaceutical industries and – in the immediate future – for use in the area of human genetics. The company, which is on the Paris Stock Exchange, (Marché Euronext) achieved a turnover to the amount of 994 million Euro in 2005. With 5,570 employees, 890 of these in research development, bioMérieux is represented worldwide in more than 130 countries by 33 business locations and a comprehensive distribution partner network. Profos AG, founded in 2000 by Regensburg University with 49 employees in the area of so-called phage-ligand technology, is one of the leading enterprises in the development of innovative technology for the detection of bacteria and bacterial components. Both companies wish to combine their competence by agreeing to work on the development of new, innovative diagnostic techniques for the detection of bacteria detrimental to health in food products, and to be able to make quick and inexpensive test systems available.
For more information see: